Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nihon Chouzai Co ( (JP:3341) ) just unveiled an update.
Nihon Chouzai Co., Ltd. announced a revision of its dividend forecast for the fiscal year ending March 2026, deciding not to pay any interim or year-end dividends. This decision aligns with the company’s support for a tender offer by AP86 Co., Ltd., which aims to take the company private and delist its shares. Additionally, the company will abolish its shareholder benefits program following the successful completion of the tender offer, marking a significant shift in its shareholder engagement strategy.
More about Nihon Chouzai Co
Nihon Chouzai Co., Ltd. operates in the healthcare industry, focusing on pharmaceutical services and products. The company is listed on the Tokyo Stock Exchange Prime Market and is known for its commitment to returning profits to shareholders while ensuring growth through internal reserves.
Average Trading Volume: 200,491
Technical Sentiment Signal: Buy
Current Market Cap: Yen97.25B
See more insights into 3341 stock on TipRanks’ Stock Analysis page.